Medicare Pilot Expands GLP-1 Coverage for Weight Loss Through 2027
A new Medicare pilot program launched July 1, 2026, allows beneficiaries with Part D coverage to access GLP-1 weight loss drugs for $50 per month through December 2027. Eligibility includes patients with BMI 35 or above, or lower BMIs with heart failure, uncontrolled hypertension, chronic kidney disease, prediabetes, or cardiovascular disease. Previously, Medicare covered GLP-1s only for diabetes management, forcing patients to wait until conditions worsened to qualify. The pilot aims to test whether expanded access reduces hospitalizations and overall healthcare costs.
This sets a precedent that could pressure state Medicaid programs to expand GLP-1 coverage criteria, as providers and beneficiaries compare Medicare's broader access to Medicaid's typically restrictive obesity drug policies.
Managed Care · Pharmacy
You might also like